[The role of adhesion molecules for assessing the effectiveness of biological treatment of patients with inflammatory bowel disease].

医学 英夫利昔单抗 溃疡性结肠炎 细胞粘附分子 炎症性肠病 胃肠病学 内科学 选择素 免疫学 移植 疾病
作者
Boldyreva On
出处
期刊:PubMed 卷期号: (5): 119-25
链接
标识
摘要

One of the key links of pathological inflammatory process is the formation factors of adhesion. They play a leading role in the formation of inflammatory infiltration of the mucosa of the colon. Changes in the levels factors of adhesion under the influence of biological therapy are not well understood. In this regard, the aim of our study was to investigate the influence of biological therapy (infliximab, mesenchymal stromal cells) on the level of adhesion molecules in patients with IBD. Investigated the role of adhesion molecules to evaluate the effectiveness of treatment in this group of patients. Was examined 30 patients with IBD. Of these, 16 patients with ulcerative colitis (UC) and 14 patients with Crohn's disease (CD). Of these, 16 patients received infliximab 5 mg/kg body weight, 14 patients with IBD who underwent a comprehensive anti-inflammatory therapy with the introduction of MSC culture. Before and after treatment with infliximab, MSC transplantation was carried out a study of the clinical blood test, CRP, determined by the level of adhesion molecule L-selectin, E-selectin, P-selectin, integrin - sVCAM-1 in serum by ELISA Under the influence of infliximab for all IBD patients had significantly lower levels of P-selectin, E-selectin, integrin - sVCAM-1. In the group of patients after MSC transplantation rates of P-selectin, E-selectin was significantly decreased and the level of integrin - sVCAM-1 decreased slightly. The level of L-selectin in patients both after MSC transplantation and therapy with infliximab is practically not reduced, which serves as a reflection of chronic autoimmune inflammation, and the basis for long-term use of biological therapy in IBD. Adhesion molecule P-selectin, E-selectin, integrin - sVCAM-1 decreased more rapidly under the influence of infliximab in patients with IBD because of the mechanism of drug action (suppression of the synthesis of core inflammatory cytokine TNF-alpha). After transplantation of MSCs P-selectin, E-selectin, integrin - sVCAM-1 decreased more slowly due to the fact that the maximum positive effect of MSCs developed after 1 month. P-selectin, E-selectin, L-selectin, integrin - sVCAM-1 are the modern markers of inflammation and can be used to evaluate the effectiveness of biological therapy in IBD and the prognosis of the disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏应助liugm采纳,获得10
1秒前
1秒前
maione发布了新的文献求助10
2秒前
2秒前
2秒前
Cat应助33采纳,获得10
3秒前
谦让的雅青完成签到,获得积分10
3秒前
Tian发布了新的文献求助10
3秒前
研友_Z7myEL完成签到,获得积分10
4秒前
jianlingzhang发布了新的文献求助10
4秒前
orixero应助wili小云朵采纳,获得10
4秒前
6秒前
6秒前
大马哈发布了新的文献求助10
7秒前
valorb完成签到,获得积分10
10秒前
momo发布了新的文献求助30
11秒前
11秒前
14秒前
15秒前
yiyi发布了新的文献求助30
15秒前
16秒前
16秒前
17秒前
qpp发布了新的文献求助10
19秒前
领导范儿应助张嘉佳采纳,获得10
20秒前
20秒前
xiaofeiyan发布了新的文献求助10
20秒前
齐天大圣完成签到,获得积分10
21秒前
正在努力进步的科研小晴完成签到,获得积分10
23秒前
医疗废物专用车乘客完成签到,获得积分10
23秒前
momo完成签到,获得积分10
25秒前
田田发布了新的文献求助10
25秒前
26秒前
共享精神应助哈哈哈采纳,获得10
26秒前
26秒前
今天睡够觉完成签到,获得积分10
27秒前
28秒前
Jasper应助深情夏彤采纳,获得10
30秒前
orixero应助123123采纳,获得10
30秒前
毛豆爸爸应助雪白砖家采纳,获得10
30秒前
高分求助中
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 1600
Exploring Mitochondrial Autophagy Dysregulation in Osteosarcoma: Its Implications for Prognosis and Targeted Therapy 1500
LNG地下式貯槽指針(JGA指-107) 1000
LNG地上式貯槽指針 (JGA指 ; 108) 1000
QMS18Ed2 | process management. 2nd ed 600
LNG as a marine fuel—Safety and Operational Guidelines - Bunkering 560
Clinical Interviewing, 7th ed 400
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2938640
求助须知:如何正确求助?哪些是违规求助? 2595996
关于积分的说明 6991751
捐赠科研通 2238632
什么是DOI,文献DOI怎么找? 1188810
版权声明 590079
科研通“疑难数据库(出版商)”最低求助积分说明 582031